98%
921
2 minutes
20
Purpose: To estimate the incidence of trilateral retinoblastoma in patients with retinoblastoma.
Design: Systematic review and meta-analysis.
Methods: We searched Medline and Embase for scientific literature published between January 1966 and July 2015 that assessed trilateral retinoblastoma incidence. We used a random-effects model for the statistical analyses.
Results: We included 23 retinoblastoma cohorts from 26 studies. For patients with bilateral retinoblastoma the unadjusted chance of developing trilateral retinoblastoma across all cohorts was 5.3% (95% confidence interval [CI]: 3.3%-7.7%); the chance of pineal trilateral retinoblastoma was 4.2% (95% CI: 2.6%-6.2%) and the chance of nonpineal trilateral retinoblastoma was 0.8% (95% CI: 0.4%-1.3%). In patients with hereditary retinoblastoma (all bilateral cases, and the unilateral cases with a family history or germline RB1 mutation) we found a trilateral retinoblastoma incidence of 4.1% (95% CI: 1.9%-7.1%) and a pineal trilateral retinoblastoma incidence of 3.7% (95% CI: 1.8%-6.2%). To reduce the risk of overestimation bias we restricted analysis to retinoblastoma cohorts with a minimum size of 100 patients, resulting in adjusted incidences of 3.8% (95% CI: 2.4%-5.4%), 2.9% (95% CI: 1.9%-4.2%), and 0.7% (95% CI: 0.3%-1.2%) for any, pineal, and nonpineal trilateral retinoblastoma, respectively, among patients with bilateral retinoblastoma. Among hereditary retinoblastoma we found an adjusted trilateral retinoblastoma incidence of 3.5% (95% CI: 1.2%-6.7%) and a pineal trilateral retinoblastoma incidence of 3.2% (95% CI: 1.4%-5.6%).
Conclusion: The estimated incidence of trilateral retinoblastoma is lower than what is reported in previous literature, especially after exclusion of small cohorts that were subject to overestimation bias in this context.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ajo.2015.09.009 | DOI Listing |
Ophthalmic Genet
June 2025
Oculoplasty and Ocular Oncology services, Dr. Shroff's Charity Eye Hospital, New Delhi, India.
Retinoblastoma is a pediatric ocular malignancy caused by biallelic inactivation of the gene, with genetic testing crucial for determining heritability. This retrospective observational study analyzed the genotypic and phenotypic profiles of 200 RB patients from North India who underwent genetic testing at a tertiary eye hospital between January 2022 and April 2024. Targeted gene analysis was performed using next-generation sequencing on blood samples, with methylation specific-multiplex ligation-dependent probe amplification detecting large deletions or duplications.
View Article and Find Full Text PDFJ Pediatr Hematol Oncol
July 2025
Departments of Pediatric Oncology.
Background: It has been reported that the risk of second malignant neoplasms (SMNs) in long-term follow-up patients with heritable retinoblastoma (Rb) is significantly increased compared with patients with non-heritable Rb and the general population. In this study, we investigated the types, frequencies, clinical and pathologic features, potential risk factors, and outcomes of SMNs occurring in a large group of retinoblastoma patients that were diagnosed, treated, and followed up for a long time in our Pediatric Oncology unit.
Methods: Our study comprehensively analyzed records of Rb patients followed up at Hacettepe University Pediatric Oncology Department over a 51-year period from January 1972 to January 2023.
Ophthalmol Retina
September 2025
Departments of Radiology and Neurosurgery, Weill Cornell Medical College, New York, New York.
Objective: To determine the feasibility, safety, and efficacy of ophthalmic artery chemosurgery (OAC) for very young children who have unilateral and bilateral retinoblastoma.
Design: Retrospective, consecutive review of all children with retinoblastoma (unilateral and bilateral) treated with OAC in the first 3 months of life or, if weighing <6 kg, treated at the Memorial Sloan Kettering Cancer Center.
Participants: All children with retinoblastoma (unilateral or bilateral) treated with OAC (17 patients) in the first 3 months of life or weighing <6 kg.
Klin Monbl Augenheilkd
March 2025
Ocular Oncology Department, Jules-Gonin Eye Hospital, Lausanne, Switzerland.
Klin Monbl Augenheilkd
April 2025
Ocular Oncology Department, Jules-Gonin Eye Hospital, Lausanne, Switzerland.